Who
Markus Warmuth
President & CEO
Company insider
Files Form 4 as: President & CEO, Monte Rosa Therapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $1.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Apr 2021
- Last trade
- 16 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 17 Jul 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $220K9,500 at $23.18 | filing |
| 16 Jul 2026filed 17 Jul 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $220K9,500 at $23.18 | filing |
| 1 Jun 2026filed 2 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $97K4,998 at $19.41 | filing |
| 1 Jun 2026filed 2 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,232468 at $19.73 | filing |
| 1 Jun 2026filed 2 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $97K4,998 at $19.41 | filing |
| 1 Jun 2026filed 2 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,234468 at $19.73 | filing |
| 1 May 2026filed 5 May 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K5,467 at $18.92 | filing |
| 1 May 2026filed 5 May 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K5,467 at $18.92 | filing |
| 14 Apr 2026filed 15 Apr 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K8,000 at $17.64 | filing |
| 14 Apr 2026filed 15 Apr 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $141K8,000 at $17.64 | filing |
| 2 Mar 2026filed 4 Mar 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $98K5,466 at $17.92 | filing |
| 2 Mar 2026filed 4 Mar 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $98K5,466 at $17.92 | filing |
| 7 Jan 2026filed 9 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $86K3,707 at $23.24 | filing |
| 7 Jan 2026filed 9 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $35K1,450 at $23.88 | filing |
| 7 Jan 2026filed 9 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,593309 at $24.57 | filing |
| 7 Jan 2026filed 9 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $86K3,707 at $23.24 | filing |
| 7 Jan 2026filed 9 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $35K1,450 at $23.88 | filing |
| 7 Jan 2026filed 9 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,592309 at $24.57 | filing |
| 5 Jan 2026filed 5 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $154K10,135 at $15.17 | filing |
| 5 Jan 2026filed 5 Jan 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $154K10,135 at $15.17 | filing |
News
Investors Buy Large Volume of Monte Rosa Therapeutics Call Options (NASDAQ:GLUE)GLUE · themarketsdaily.com · 19 Oct 2026Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)GLUE · tickerreport.com · 16 Oct 2026Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded to "Hold" at UBS GroupGLUE · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Markus Warmuth; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.